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A B S T R A C T
Since the introduction of electronic cigarettes (e-cigarettes) in 2003, the technology has advanced allowing for
greater user modifications, with users now able to control voltage, battery power, and constituents of the e-
cigarette liquid. E-cigarettes have been the subject of a growing body of research with most research justifiably
focused on the chemical makeup and risk analysis of chemicals, metals, and particulates found in e-cigarette
liquids and vapor. Little research to date has focused on assessing the risks associated with the drug delivery unit
itself and its potential for use as an illicit drug delivery system. In light of this, a range of illicit drugs was
researched focusing on pharmacodynamics, usual method of administration, the dosage required for toxicity,
toxic effects, and evidence of existing use in e-cigarettes in both literature and online illicit drug forums. A
systematic literature search found evidence of current use of e-cigarettes to vape almost all illicit drug types
analyzed. This presents both a potential population health risk and a management issue for clinicians. It also
raises the issue of policing illicit drugs due to potential altered characteristic smells and storage within e-ci-
garette fluids. E-cigarettes are a viable illicit drug delivery system with evidence both inside and outside of the
formal medical literature detailing their potential use for drug delivery of a wide range of illicit and legal drugs.
1. Introduction
The electronic cigarette (e-cigarette) first appeared in 2003 as an
alternative to traditional tobacco cigarettes for nicotine delivery
(Schraufnagel et al., 2014). Since its introduction, e-cigarette awareness
and use has grown rapidly (Adkison et al., 2013; Schraufnagel et al.,
2014) expanding into the global market with United States (U.S.) retail
sales expected to approach $10 billion by 2017 (Besaratinia and
Tommasi, 2017), and presenting a challenge for tobacco regulatory
bodies and health departments (WHO, 2014). The past six years have
seen a ten-fold increase in the number of adult smokers seeking to
transition from smoking to vaping, with recent estimates showing more
than 4 million Americans are using e-cigarette devices (Besaratinia and
Tommasi, 2017). In 2014, e-cigarettes became a more common tobacco
product among U.S. youth than traditional cigarettes (Eggers et al.,
2017) and a survey of students in Wales, UK found that among year 11
students (aged 15–16) 37.3% had used an e-cigarette (ever) where only
26.5% had smoked a traditional cigarette (ever) showing the increased
popularity of e-cigarettes among youth (Lacy et al., 2017). This has
warranted an influx of research around both the technology and its
delivery method.
Most studies to date have examined the chemical composition of e-
cigarette vapor and liquid. This has included: nicotine delivery con-
centrations per puff (Czogala et al., 2014; Goniewicz et al., 2014;
Pellegrino et al., 2012); e-cigarette liquid nicotine concentrations
(Pisinger and Døssing, 2014); exhaled concentrations of propylene
glycol (Pellegrino et al., 2012; Schober et al., 2014; Schripp et al.,
2013) and its effects (Werley et al., 2011); glycerine vapor concentra-
tions (Pellegrino et al., 2012) and its effects (Farsalinos and Polosa,
2014); acetone vapor concentrations (Schripp et al., 2013); for-
maldehyde vapor concentrations (Goniewicz et al., 2014, 2013; Schripp
et al., 2013); nitrosonornicotine presence in vapor (Goniewicz et al.,
2014; WHO, 2007); tobacco-specific nitrosamine presence in vapor
(Farsalinos and Polosa, 2014; McAuley et al., 2012); metals in vapor
(Goniewicz et al., 2014; Williams et al., 2013) and flavoring con-
centrations and toxicity (Bahl et al., 2012; Farsalinos et al., 2015;
Khlystov and Samburova, 2016). Particulate matter (PM) levels have
also been researched with studies showing that e-cigarettes produce
PM10, PM2.5 and PM1.0 (Pellegrino et al., 2012; Schober et al., 2014),
though these levels are lower than traditional cigarettes (Czogala et al.,
2014; Pellegrino et al., 2012) and differ depending on e-cigarette liquid
brand and composition (Czogala et al., 2014; Schober et al., 2014).
Common consensus is that e-cigarette users do not inhale the carcino-
gens contained in tars (Douglas et al., 2015), and the e-cigarette liquids
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are not heated to the point of combustion, therefore the health effects
relating to the use of e-cigarettes are likely to be lower than for tradi-
tional cigarettes even though the long-term effects are largely un-
known. There has also been a growing interest in the use of e-cigarettes
as a tobacco smoking cessation device, with some studies showing
promise for its use (Barbeau et al., 2013; Bullen et al., 2013), while
others provide conflicting results (Orr and Asal, 2014) or suggest e-
cigarettes may be a pathway to increased youth tobacco smoking (Dutra
and Glantz, 2014; Leventhal et al., 2015). Despite this influx of re-
search, some concerns have arisen. A serious concern addressed by a
meta-analysis by Pisinger and Døssing is that of academic bias. They
claimed that 34% of included authors on papers describing e-cigarette
toxicity had a conflict of interest and that the majority of their included
studies were either funded or supported to some degree by e-cigarette
manufacturers (2014).
Another concern identified in the research is the lack of academic
focus on the risk analysis of the e-cigarette drug delivery unit. Since the
release of the first-generation e-cigarette, which was cigarette-shaped
(Rom et al., 2015), three generations have followed. Second generation
devices exhibited a change in style as well as introducing elements of
larger rechargeable batteries and refillable e-cigarette fluid tanks
(Dawkins et al., 2015). Third generation devices added the ability to
modify the voltage provided to the atomizer to alter the atomizer
temperature (Dawkins et al., 2015), generally up to 212 °C (Giroud
et al., 2015), with consequent effects on the amount of vapor produc-
tion. Further to this, third generation devices, with larger battery ca-
pacity and unit size, allowed the attachment of larger tanks allowing for
greater e-cigarette liquid storage (Dawkins et al., 2015). These gen-
erational changes as well as the advanced user’s ability to personally
modify devices add a difficult to control variable when assessing the
risk of the e-cigarette unit, especially considering the potential to de-
liver drugs of abuse.
Despite the growing catalog of research and studies surrounding e-
cigarettes and the fact that inhalation has been noted as an increasingly
common route of administration of illicit drugs due to the rapid onset of
action, very little research has focused on possible alternative uses of e-
cigarette technology (Bell and Nida, 2015). Since e-cigarettes have
proved to be an effective nicotine drug delivery system (Schroeder and
Hoffman, 2014), the question arises as to whether other illicit drugs are
also able to be effectively delivered by e-cigarettes. Referring to the
most commonly abused illicit drugs in Australia (AIHW, 2008) and
around the world, the pharmacodynamics and pharmacokinetics of
these drugs indicate the potential for the use of e-cigarette technology
as a novel drug delivery system. The vaporization of cannabis had been
proposed well before the first e-cigarette (Gieringer, 2001) with studies
demonstrating that vaporization of medicinal cannabis produces
plasma concentrations of Δ-9-tetrahydrocannabinol (Δ-9-THC) com-
parable to traditional cannabis combustion smoking (Abrams et al.,
2007; Gieringer et al., 2004).
Due to the limited pool of literature on illicit drug delivery via e-
cigarettes (Giroud et al., 2015), the question arises as to what other
illicit drugs are being used via e-cigarette technology. In addition to
summarizing the current literature relating to this topic, this paper,
investigates the plausibility and risk of e-cigarette technology as a drug
delivery system for illicit drugs. Drugs assessed include: cannabis,
synthetic cannabinoids (SCs), synthetic cathinones, benzoylmethy-
lecgonine (cocaine), gamma-hydroxybutyric acid (GHB), heroin, fen-
tanyl, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenediox-
ymethamphetamine (MDMA), and methamphetamine. These drugs will
be reviewed in terms of their known mechanisms of action, the dosage
required for toxicity and toxic effects. Finally, the literature will be
reviewed for evidence of e-cigarette use for each drug and where no
evidence can be found illicit drug use internet forums will be accessed
for preliminary evidence of possible usage.
The term ‘vaping’ is used both colloquially and in the literature to
describe the through mouth inhalation of a vaporized product from a
device that uses electrical power to heat the product to the point of
vaporization. The product can refer to substances with desired inhala-
tion effects such as nicotine dissolved in e-liquids (usually a mix of
propylene glycol and glycerine); crushed plant material placed directly
into the vaporizing device; concentrated extracts from plant materials
in the form of thick waxes or oils either on their own or diluted in e-
liquid; or substances directly dripped onto the hot coil to produce
vapor. Vaping devices can be classified into two broad categories por-
table vaporizing devices, powered by batteries, or table-top vaporizers.
For the purposes of this paper ‘e-cigarettes’ is used as a collective term
for all types of portable vaporizing devices, not only those that resemble
traditional cigarettes. ‘Vaping’ can refer to use of either e-cigarettes or
table-top vaporizers or both unless specified.
2. Methods
2.1. Search strategy
A systematic search for the use of electronic cigarettes or other
vaping devices to vape illicit drugs in the literature was conducted on
14 March 2018. The databases employed were ProQuest, Scopus, Web
of Science and PubMed. The literature search was left deliberately
broad to ensure all results involving the use of electronic cigarettes or
other vaping devices to vape illicit drugs were captured. The search
strategy employed for all databases was as follows: ab(cannabis OR
THC OR cathinone OR alpha-PVP OR MDPV OR methylone OR me-
phedrone OR cocaine OR GHB OR "gamma-hydroxybutyric acid" OR
heroin OR fentanyl OR oxycodone OR opioid OR MDA OR "3,4-me-
thylenedioxyamphetamine" OR amphetamine OR methamphetamine
OR MDMA OR "3,4-methylenedioxymethamphetamine" OR Molly OR
ecstasy OR "synthetic cannabinoid" OR cannabinoid OR "bath salts" OR
"legal high") AND (vapor OR vapor OR vaping OR vape OR e-cigarette
OR "electronic cigarette" OR e-cig OR "e-cig" OR vaporizer OR vaporizer
OR vaporizer) limited to English (abstract only). Illicit drug user forums
were accessed in lieu of formal medical literature to assess evidence for
the use of illicit drugs with e-cigarettes. Forum websites were searched
using the same terms as the academic literature search, however, col-
loquial and street names were used in the search. The following web-
sites were utilized: www.bluelight.org/vb/content/; https://drugs-
forum.com/forum/index.php; https://www.reddit.com/r/Drugs/;
https://www.quora.com; and https://www.erowid.org. Evidence of use
was subjectively assessed via forum threads and user comments directly
indicating either personal or known associate use.
2.2. Search selection
The initial database search identified 1603 papers, which once du-
plicates were removed left 1118 results (Fig. 1). Of those, 935 records
were eliminated because of their irrelevance to the topic, and a further
145 were removed following full-text screening as they did not provide
specific examples of the use of electronic-cigarette style devices to vape
illicit drugs. The remaining 38 articles were used in the final analysis,
articles relating to cannabis use in e-cigarettes are marked in the re-
ference list with a *; articles relating to any other type of illicit drug use
in e-cigarettes are marked with a ^.
3. Results
3.1. Cannabis
Cannabis (marijuana) is currently the most widely used illicit drug
in the world (3.5% adults), with the highest rates of past year usage in
Oceania (10.3%) (Gowing et al., 2015). It is usually administered orally
or by inhalation (Grotenhermen, 2003; Pillay, 2013). The theory behind
vaping cannabis is a reduction in inhalation of smoke-related toxins and
carcinogens including tar, carbon monoxide and ammonia (Budney
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et al., 2015), and in particular harm minimization for medicinal can-
nabis users (Gieringer et al., 2004; Gieringer, 2001; Van Dam and
Earleywine, 2010). Cannabis users perceive vaping to be less harmful to
their health than smoking methods (Budney et al., 2015) and those who
use vaporizers claim to experience less respiratory irritation (Loflin and
Earleywine, 2015). A survey of those who had ‘ever-vaped’ cannabis
reported that vaping tastes better than smoking (39.3% of users); is
healthier (42.9%); and produces a stronger high (58.1%) (Morean et al.,
2015). Vaping of cannabis has the potential to decrease the risk of
second-hand smoke inhalation (Cranford et al., 2016) and might reduce
the number of youths becoming addicted to nicotine due to ‘mulling’ of
the cannabis with tobacco before smoking (Gartner, 2015).
The main active component of cannabis is Δ-9-tetrahydrocannabinol
(Δ-9-THC). Δ-9-THC acts as a partial agonist (Mills et al., 2015) equally
upon the cannabinoid receptors CB1 and CB2 (Adams and Martin, 1996;
Grotenhermen, 2003). CB1 receptors are primarily present in the central
and peripheral nervous system and produce the main effects of drug
intoxication, whilst CB2 receptors are found primarily in immune cells
and do not contribute to the effects of intoxication (Grotenhermen,
2003). Activation of these receptors appears to inhibit the release of a
number of neurotransmitters including acetylcholine, norepinephrine,
GABA, dopamine, serotonin, and prostaglandins (McGuigon, 2006;
Pillay, 2013). Δ-9-THC and its active metabolite 11−OH-THC both
contribute to the psychotropic effects of cannabis (Greydanus et al.,
2015). Inhalation of vaporized cannabis produces pharmacokinetic
curves and plasma concentrations of Δ-9-THC and its active metabolite
that are similar to those from smoking cannabis (Hartman et al., 2015;
Swortwood et al., 2016).
3.1.1. Dosage required for toxicity
Toxicity is thought to be affected largely by individual prior ex-
perience and tolerance level (Benowitz, 2012a). Dosages of up to
9000mg/kg of Δ-9-THC have been administered to monkeys with no
reported deaths (Thompson et al., 1973). Inhaled dosages> 7.5mg/m2
can produce symptoms such as hypotension, panic, anxiety, myoclonic
jerking, delirium, respiratory depression, and ataxia in adults (Turner
Fig. 1. Systematic review selection process.




Effects are dependent on dose (Grotenhermen, 2003; Hoch et al.,
2015), as well as the frequency of use and method of preparation (Hoch
et al., 2015). Toxic effects can include: reduced psychomotor and
cognitive performance (Solowij et al., 2001), anxiety and panic attacks
(Benowitz, 2012a; Grotenhermen, 2003), psychotic episodes (Hall,
1994), delusions, hallucinations, slurred speech, mood swings, ortho-
static hypotension and tachycardia (Benowitz, 2012a; Cavazos-Rehg
et al., 2016; Leikin and Paloucek, 2007). There are reports of increased
rates of conjunctivitis regardless of route of administration, as well as
the exacerbation of pre-existing psychotic diseases (Turner and
Agrawal, 2017) and development of cannabinoid hyperemesis syn-
drome in long-term users, particularly those consuming cannabis with a
high Δ-9-THC content (Galli et al., 2011). There is also a case report of
acute respiratory failure in a patient who had vaped cannabis oil ap-
proximately once a week for several years but had never smoked (He
et al., 2017).
3.1.3. E-cigarette usage
Vaping is a highly prevalent mode of use among medical marijuana
patients, with 39% of survey respondents having vaped in the past
month. However, it is rarely an explicit route of administration, often
combined with others including smoking, oral and topical (Cranford
et al., 2016). There have been a number of e-cigarette accessories, in-
cluding interchangeable coil heads, specifically designed and adapted
for use vaping dry plant material, oil concentrates, and cannabis-based
e-liquids (Giroud et al., 2015). Numerous survey studies investigating
the prevalence of cannabis vaping among adults and youth are sum-
marized in Table 1.
A temperature of approximately 200 °C is sufficient for decarbox-
ylation and vaporization (Lanz et al., 2016) with the cannabinoids
vaporizing at temperatures ranging from 157 to 220 °C (Troutt and
DiDonato, 2017). Exposure to higher temperatures, or prolonged ex-
posure to the heating coil will result in the subsequent formation of
toxic pyrolytic by-products (Giroud et al., 2015). In addition, a study of
the common thinning agents mixed with cannabis oil prior to use in e-
cigarettes found that at 230 °C a number of toxic aldehydes, including
acetaldehyde and formaldehyde were produced (Troutt and DiDonato,
2017). Several brands of bench-top electronic vaporizers were analyzed
using a vaporization temperature of 210 °C with vapor recovery of Δ-9-
THC varying between 54.6–82.7% and cannabidiol (CBD) from 51.4 to
70.0%. Decarboxylation was>97.3% for Δ-9-THC for all devices (Lanz
et al., 2016).
Following the legalization of marijuana in some U.S. states there has
been an influx of e-liquids containing cannabinoids to the marketplace
(Peace et al., 2016a) where the sale of prefilled cannabis oil cartridges
(for vaporization) in Colorado increased by 163% between February
2015 and February 2016 (Troutt and DiDonato, 2017). However, there
is often a significant discrepancy between the labeling of products and
the actual contents. Two commercial marijuana e-liquids for use in e-
cigarettes which claimed to contain 3.3 mg/ml CBD were found to
contain 6.5 and 7.6mg/ml CBD (Peace et al., 2016a). In a separate
study analysis of another cannabis e-liquid which claimed to contain
69.1% Δ-9-THC and 1% CBD was shown to contain 42.6% Δ-9-THC (w/
v) and 0.5% CBD (w/v) (Peace et al., 2016b). A study analyzing 84
cannabidiol (CBD) extracts for sale as medical products found that only
31% contained a CBD content that corresponded with the label (within
10%), 43% exceeded the amount shown on the label, and 26% con-
tained less CBD than shown (Bonn-Miller et al., 2017).
In addition to using vaping devices such as e-cigarettes to vape e-
liquids and cannabis plant material, the devices are also employed to
consume high potency cannabis concentrates (Budney et al., 2015).
Concentrates, obtained from solvent extraction of the plant, contain
significantly higher Δ-9-THC content (∼80% c.f. ∼10%) (Cavazos-
Rehg et al., 2016; Daniulaityte et al., 2015), and can be easily vaporized
(Blundell et al., 2018b). Concentrates can be divided into four general
categories: kief from dry extraction processes such as dry-ice; hash oil
(also known as bubble) from water extraction; butane honey oil (BHO)
(also known as wax, shatter or budder) from butane solvent extraction
(other organic solvents can also be used); and CO2 oil from CO2 ex-
traction (Raber et al., 2015). Because the extraction process is not
regulated and is often performed in clandestine laboratories, there is a
wide variation in the purity and potency of these products (Budney
et al., 2015). Lifetime cannabis vapers reported a preference for hash oil
(45.5%), and dried buds (39.4%) over Δ-9-THC wax (15.2%) (Morean
et al., 2015). Analysis of concentrates found that 83.3% of samples
contained some residual solvents, with isopentane the most common
residual solvent identified (29.8%) (Raber et al., 2015). Pesticides were
also identified in 33.3% of concentrate samples (Raber et al., 2015).
Recently, there has been a proliferation of advertising in states that
have legalized medical marijuana. According to a preliminary study
reported by Carlini et al. (2017), approximately 20% of the advertise-
ments they analyzed featured concentrates or devices used to consume
concentrates.
A new method of partaking in cannabinoids is via a technique
known as ‘dabbing’ (Greydanus et al., 2015; Krauss et al., 2015).
Dabbing involves heating a cannabis concentrate, often BHO, to high
temperatures and inhaling the resulting vapor (Cavazos-Rehg et al.,
2016) often the ‘dab’ of oil is vaporized on the end of a glass rod that
has been heated with a blowtorch (Giroud et al., 2015; Raber et al.,
2015) or used in a vaporizer or electronic cigarette (Zhang et al., 2016).
The slang term ‘dabs’ seems to be used regardless of the type of con-
centrate (e.g., BHO) being used or the mode of inhalation (e.g., via a
dab rig or vape pens; Daniulaityte et al., 2017).
Accurate determination of rates of e-cigarette use for cannabis is
difficult to determine due to the wide variation in the types of no-
menclature used for these devices. For example, e-cigarettes, vape pens,
and e-vaporizers (usually a portable electronic vaporizer that isn’t
shaped like a traditional cigarette) are all types of portable electronic
vaporizers, whereas ‘electronic vaporizer’ can mean e-vaporizer or can
be referring to a table-top non-portable system. E-cigarettes can be used
as a general term to describe any portable vaporization device (as it is
in this paper) or it might specifically refer to small disposable e-cigar-
ettes which very closely resemble traditional cigarettes. Additionally,
terms used interchangeably with e-cigarettes include vape-mod, box-
mod, personal vaporizer, and specifically for cannabis use e-joint or
vape joint. Hakkarainen (2016) has proposed more defined terminology
where the term e-cigarette is used exclusively for tobacco vaporization
whereas vape-pen could be used as a term for portable vaporizers for
cannabis. The difficulty here is the obvious cross-over between these
units with individuals often using their e-cigarettes usually used for
nicotine consumption for more illicit drugs including cannabis. Adding
to this intricacy is the novel use of existing terminology. A series of
semi-structured interviews with young adults revealed an increasing
complexity in the use of terms as common as the word ‘smoking’ with
confusion as to whether the word smoking refers to tobacco, cannabis
or either. Terminology seemed to vary by geographical location with
one respondent claiming that in Colorado the term ‘smoke’ indicated
marijuana use, but in Texas, the term would mean tobacco use
(McDonald et al., 2016).
3.2. Synthetic cannabinoids
Synthetic cannabinoids (SCs) consist of hundreds of designer drugs
(Castaneto et al., 2014) based off the structure of Δ-9-THC, with 160
SCs currently being monitored by the European Monitoring Centre for
Drugs and Drug Addictions (EMCDDA) (Kim et al., 2017). They are
particularly attractive to young people due to: a lack of available
methods of detection in bodily fluids, largely caused by a regular influx
of new structural entities to the market; the perception that the drugs
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are natural and therefore legal and/or harmless; and the ease of access,
often via both convenience stores and the internet labelled as ‘legal
high’ or ‘not for human consumption’ (Castellanos and Gralnik, 2016;
NDEWS, 2015; Weinstein et al., 2017). Street names for SCs vary by
country; the most common are ‘K2’ in the United States, ‘Spice’ in
Europe, and ‘Kronic’ in Australia and New Zealand (Zawilska and
Andrzejczak, 2015). Several countries have reported the identification
of products that are being sold as cannabis resin on the illicit market
that consist of synthetic cannabinoids (Castellanos and Gralnik, 2016).
SCs are available as a plant preparation, where the cannabinoids are
dissolved and sprayed onto various herbs, as capsules and in e-liquid
formations (Schifano et al., 2017). The usual routes of administration
are inhalational, intranasal, and oral (Vandrey et al., 2012).
Most SCs exhibit a full agonist effect on CB1 receptors (Koller et al.,
2013), and to a lesser extent, CB2 receptors (Mills et al., 2015) with a
faster time to peak of onset effect and a shorter duration of action than
natural cannabinoids (DeBruyne and Boisselier, 2015; Schifano et al.,
2017). However, some have been identified as full agonists at both the
CB1 and CB2 receptors which results not only in greater potency but
also potentially more severe adverse effects (Blundell et al., 2018b).
Activation of CB1 receptors is associated with the drug’s effects (Mills
et al., 2015), with most synthetic cannabinoids exhibiting significantly
stronger affinity than Δ-9-THC when binding to CB1 receptors (ElSohly
et al., 2014), and some mono-hydroxylated SC metabolites retaining
nanomolar binding affinity for CB1 receptors (Tai and Fantegrossi,
2017). The higher affinity of SCs and the presence of multiple active
metabolites may explain the increased morbidity and mortality seen
with SC abuse when compared with cannabis (Tai and Fantegrossi,
2017).
3.2.1. Dosage required for toxicity
Dosage of synthetic cannabinoids is often relatively low due to the
high affinity of the drugs for CB1 receptors (Castaneto et al., 2015).
Toxic effects have been reported in blood serum levels of JWH-018
lower than 0.10 ng/ml (Hermanns-Clausen et al., 2013), while some
regular users who have built up tolerance to the drug can demonstrate
Table 1
Summary of survey findings describing current use of vaporizers to consume cannabis. Unless specified ‘vaporizer’ use may be referring to table-top vaporizers, or
vape-pen (e-cigarette) style-vaporizers or a combination of both.
Ref. Year Study Description Relevant Findings
(Hindocha et al., 2016) 2013-
2014
Global Drug Survey, online, adult, past year cannabis
use, n= 33,687
5.8% of Australian cannabis users had used a vaporizer as the route of
administration compared to 11.2% of respondents from the United States and
13.3% from Canada.
(Schauer et al., 2016) 2014 United States, Summer Styles Survey, adults, n=4269 7.6% of past 30-day cannabis users had used a vaporizer or other electronic
device to consume cannabis, compared with 9.9% of ever-cannabis users.
(Lankenau et al., 2017) 2014-
2015
United States, Los Angeles, young adult (18–26 years),
current cannabis users, medical vs recreational use,
n=366
44.3% of users had used an electronic vaporizer such as an e-cigarette or vape-
pen in the past 90 days, this value increased to 51.9% when considering only the
medical marijuana user.
(Lee et al., 2016) 2014-
2015
United States, online, adult, current cannabis users,
n=2910
61% of current cannabis users had administered cannabis via vaping; 37% had
vaped in the past 30 days; 20% reported > 100 days of vaping; and 12%
reported vaping as their preferred method of administration.
(Morean et al., 2017) 2015 United States, adult, past month nicotine e-cigarette
use, n=522
52.3% of nicotine e-cigarette users reported use of any cannabis; 17.8% reported
ever-use of an e-cigarette or vape pen to vaporize cannabis; 11.5% reported
vaping cannabis in the past month.
(Shiplo et al., 2016) 2015 Canada, adult, medical cannabis use, n=364 65.9% of medical cannabis users had ever used a vaporizer as a mode of delivery;
5.27% were current users; and 28.3% stated vaporizers were their preferred
mode of delivery. Most of the respondents claimed use of a portable vaporizer
(such as an e-cigarette) rather than a table-top vaporizer.
(Daniulaityte et al.,
2017)
2016 United States, adult, current cannabis users, n= 673 > 66% of current cannabis users had used marijuana concentrates, with about
13% reporting daily or near daily use. Of those using concentrates 66% reported
the use of a vape pen to consume cannabis.
(Morean et al., 2015) 2014 United States, Connecticut, middle and high school
students, n=3847
4.5% had used an e-cigarette to vaporize hash oil; 3.0% had used e-cigarettes to
vaporize THC-infused wax; and 6.7% had used a portable electronic vaporizer to
vaporize dry cannabis plant material.
(Eggers et al., 2017) 2015 United States, Florida Youth Tobacco Survey, middle
and high school students, n= 12,320
3.4% of middle school students and 11.5% of high school students reported ever
using a vaping device to consume cannabis.
(Mammen et al., 2016) 2015 Canada, Ontario Student Drug Use and Health Survey,
high school students, n=3171
8% of high school students reported vaping cannabis using an e-cigarette (the
value is possibly even higher if other forms of vaporizer are considered).
(Blundell et al., 2018a) 2017 UK, adult (> 16 yrs.), convenience sample, online
questionnaire, n= 2501
6.2% of respondents reported vaping cannabis (ever use); 3.6% of respondents






United States, adult, convenience sample of past
cannabis users, online survey, n=2838
53.8% of cannabis users in states without legal medical marijuana had vaped




2016 United States, youth (14–18 yrs.), convenience sample
of past cannabis users, online survey, n= 2630
35.6% of cannabis users in states without legal medical marijuana had vaped
cannabis; 50.8% of cannabis users in states with legal medical marijuana had
vaped cannabis
(Cuttler et al., 2016) – United States, adult, convenience sample of past
cannabis users, online survey, n=2459
17.3% of male cannabis users and 11.4% of female cannabis users reported their
method of use as a vaporizer; 5.4% of males and 3.1% of females reported use of
concentrates
(Cranford et al., 2016) 2014-
2015
United States, adults (> 21 yrs), medical marijuana
users, n=1485




Europe, adults, e-cig or portable e-vaporizer cannabis
users, n=55
11 responders used e-cig; 44 responders used portable e-vaporizer; most
common products used in e-cig were buds (45%) and oil (54%), in portable e-
vaporizers were buds (77%), oil (21%) and hashish (21%)
(Frohe et al., 2018) 2017 United States, college students > 18 yrs. n=270 10.7% of respondents had used a vape-pen to vape cannabis
(Johnson et al., 2016) 2013 United States, high school students, Healthy Kids
Colorado Survey, n= 25,197
6.2% (weighted) of past 30-day cannabis users stated vaporization was their
usual method of consumption of cannabis
(Jones et al., 2016) 2016 United States, college students enrolled in intro
Psychology, questionnaire, n=482
22.5% of respondents had vaped cannabis; 51.2% of past-year cannabis users
had vaped cannabis
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higher serum levels, up to 17 ng/ml, without toxic symptoms occurring
(Dresen et al., 2011). To demonstrate the variability in toxic levels, the
synthetic cannabinoid JWH-210 can produce similar toxic effects at
blood serum levels as low as 0.20 ng/ml and as high as 190 ng/ml
(Hermanns-Clausen et al., 2013). Actual toxic dosage levels are simi-
larly difficult to establish. Tonic-clonic seizures have been reported in
smoked dosages of 3 g of Spice (Pant et al., 2012). Aggression, agita-
tion, panic attack and vomiting have been reported following a smoked
dosage of 300mg of ‘Samurai King’ (Derungs et al., 2013), recurrence of
cannabis-induced psychosis following 3 g of smoked ‘Spice’ (Müller
et al., 2010) and post-traumatic stress disorder flashbacks and hallu-
cinations following a 1.5 g a day habit of smoked ‘Spice’ (Peglow et al.,
2012).
3.2.2. Toxic effects
Effects are dependent on the individual user, dosage and the parti-
cular SC and its mixture (Salani and Zdanowicz, 2015). Nausea and
vomiting, hypokalaemia, acute psychosis, panic attack, confusion, agi-
tation, blindness, deafness, mild to intense pain, severe sinus brady-
cardia or tachycardia (Andonian et al., 2017; Carlier et al., 2016),
ventricular dysrhythmias, hypo- or hyperthermia, hypo- or hypergly-
caemia (Hermanns-Clausen et al., 2013; Kersten and McLaughlin,
2015), sweating, muscle twitching, chest pain, shortness of breath,
myocardial infarction, rhabdomyolysis (Castellanos and Gralnik, 2016;
Weaver et al., 2015; Zawilska and Andrzejczak, 2015), ischaemic stroke
(Castaneto et al., 2014), excited delirium, acute kidney injury, seizures,
hallucinations, cardiotoxic effects, and coma (Trecki et al., 2015) have
been reported. Death due to cardiac ischemic event and extreme an-
xiety leading to suicide have also been reported following SC use
(Weaver et al., 2015).
3.2.3. E-cigarette usage
Blundell et al. (2018a) reviewed drug user forums and determined
that around 15% of individuals who vaped cannabis have also vaped
synthetic cannabinoids (Blundell et al., 2018b). In a survey study by the
same group 7.8% of electronic vaping device users admitted to vaping
synthetic cannabinoids. A National Early Warning System Report out of
Atlanta stated that the use of vaporization techniques involving e-ci-
garettes is becoming a popular method of use for administration of
synthetic cannabinoids (NDEWS, 2015). The manufacture of SCs in li-
quid cartridges for use in e-cigarettes has also been reported (DEA,
2016; Castellanos and Gralnik, 2016; DeBruyne and Boisselier, 2015).
These solutions are colloquially referred to as ‘Buddha-blue,’ ‘C-liquid,’
‘herbal e-liquid,’ and others (DeBruyne and Boisselier, 2015). In con-
trast, the more non-polar synthetic cannabinoids are generally sprayed
onto aromatic herbs and vaped using a dry-herb coil head fitted to an e-
cigarette rather than consumed as an e-liquid due to poor solubility
(Giroud et al., 2015).
There have also been several reports of intoxication due to vapor-
ization of synthetic cannabinoids. In 2014 there were a number of teens
treated for intoxication with cannabinoid ‘Cloud 9.’ According to police
reports the students were putting drops on their tongues, mixing it with
candy or soft drinks and using e-cigarettes to vaporize the drug (Glover,
2014). Literature case reports of patients receiving treatment for in-
toxication due to suspected or known vaping of synthetic cannabinoids
are described in Table 2.
3.3. Methamphetamine
Methamphetamine is a central nervous system stimulant that be-
longs to both the amphetamine and phenethylamine drug classes (Yu
et al., 2015) typical behavioral effects include alertness, energy, and
euphoria (Kish, 2008). Usual routes of administration are inhalational,
oral, intravenous, and intranasal (Elkashef et al., 2008). Methamphe-
tamine targets and reverses the vesicular monoamine uptake trans-
porter-2 (VMAT) (Elkashef et al., 2008). This results in rapid
accumulation of monoamines, dopamine, serotonin and norepinephrine
in the presynaptic neuron, followed by their release into the extra-
cellular space due to transporter reversal (Elkashef et al., 2008; Kish,
2008). Methamphetamine is also a weak inhibitor of monoamine oxi-
dase (MAO) resulting in a reduction of monoamine neurotransmitter
metabolism, extending their duration of effect in the synaptic cleft
(Elkashef et al., 2008).
3.3.1. Dosage required for toxicity
Methamphetamine bioavailability via inhalation (smoking) ranges
from 67% to 90% depending upon smoking technique (Cruickshank and
Dyer, 2009). Inhaled dosages above 50mg have the potential to cause
some toxicity, but specific toxic dosages are difficult to determine due
to significant variability between individuals, particularly in long-term
users. Dosages greater than 150mg are thought to be highly toxic to
non-chronic users (Cho, 1990). Long-term chronic users can tolerate
higher dosages of up to 1000mg or more (Lake and Quirk, 1984).
3.3.2. Toxic effects
Restlessness, insomnia, hyperthermia, seizures, agitation, psychosis,
paranoia (Elkashef et al., 2008), thirst, diaphoresis, paresthesia, head-
aches, aggression (Bell, 1973), angina, nausea and vomiting, halluci-
nations, palpitations, dyspnoea, ventricular fibrillation, myocardial in-
farction, tooth decay (meth mouth), coma, and renal failure (De-Carolis
et al., 2015) as well as rhabdomyolysis and suicidal ideation
(Cruickshank and Dyer, 2009) have been reported. An increase in the
rate of both hemorrhagic and ischemic stroke in young people (< 45
years) has also been reported with ischemic stroke noted to be more
common with an inhalational route of administration (Lappin et al.,
2017).
3.3.3. E-cigarette usage
Literature indicates that an increasing number of individuals are
using drug vaporization, such as e-cigarettes, as a new method of ad-
ministration for methamphetamine (NDEWS, 2015). Additionally, re-
searchers have recently shown that methamphetamine is present at
reasonable concentrations in vapor from e-cigarettes (McNeill, 2016).
While literature evidence on the use of e-cigarettes for the vaping of
methamphetamine is currently limited, internet drug forum users have
stated that they have used e-cigarettes (Fig. 2), vape pens and/or table-
top units to vaporize methamphetamine.
3.4. MDMA
3-4-Methylenedioxymethamphetamine (MDMA), also known as
‘Ecstasy’ or ‘Molly’, is an amphetamine derivative and psychostimulant
used primarily as a recreational drug to increase user empathy and
euphoria (Green et al., 2012). The usual administration routes are oral,
intranasal, inhalational, and via intravenous injection (EMCDDA,
2015c). MDMA blocks the reuptake of monoamine neurotransmitters
(norepinephrine, serotonin, dopamine) (De la Torre et al., 2004;
Steinkellner et al., 2011), with MDMA exhibiting a stronger affinity for
serotonin, and norepinephrine transporters (Rothman et al., 2001). It
also acts as a competitive substrate for monoamines and reverses
monoamine transportation, further reducing monoamine reuptake
(Sitte and Freissmuth, 2010).
3.4.1. Dosage required for toxicity
Tolerance to MDMA develops rapidly with a subsequent increase in
adverse effects due to frequent use. Toxic dosage is dependent on in-
dividual susceptibility (EMCDDA, 2015c). There is little data on toxicity
due to inhalation; however, toxic symptoms such as psychosis and
paranoia have been reported with oral dosages of 80–85mg (Ellenhorn
et al., 1997) and fatalities have been recorded following dosages of
300mg (EMCDDA, 2015c). Severe hyperthermia has been reported at
doses of 4–5mg/kg (Hahn, 2017).
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3.4.2. Toxic effects
Nausea, vomiting, restlessness, tremor, hyperreflexia, irritability,
trismus and bruxism, palpitations, confusion, aggression, psychosis,
panic attack (De la Torre et al., 2004), hyperthermia, serotonin syn-
drome, cardiac arrhythmias, hypertension, hyponatremia, seizures,
coma, death (Schifano, 2004).
3.4.3. E-cigarette usage
There is evidence on internet drug forums of users employing va-
porization techniques, such as e-cigarettes and table-top vaporizers, to
vape MDMA. In several cases, users made mention of ensuring the drug
was converted into the free-base form before vaporization. A survey by
Blundell et al. (2018a) determined that 11.7% of electronic vaping
device users have vaped MDMA.
3.5. Synthetic cathinones
One of the major classes of new psychoactive substances is synthetic
cathinones which are sold as alternatives to 3,4-methylenediox-
ymethamphetamine (MDMA) and other amphetamines, with which
they share structural similarities, or cocaine (Anizan et al., 2014;
Ellefsen et al., 2016). In 2014, 31% of the 101 new psychoactive sub-
stances (NPS) identified were synthetic cathinones (Glennon and Dukat,
2017). Cathinones are often marketed as legal highs or labelled as "bath
salts,’ ‘plant food,’ or ‘research chemicals’ often in combination with the
warning ‘not for human consumption’ in order to avoid government
legislative control (Abbott and Smith, 2015; Anizan et al., 2014;
Backberg et al., 2015; Ellefsen et al., 2016). Chemical purity in com-
mercially available ‘bath salts’ is often a problem with no quality con-
trol in manufacturing (Backberg et al., 2015). A study of 27 ‘legal high’
products identified a wide variety of synthetic cathinones, as well as
drugs from other structural classes, and samples rarely contained a
single psychoactive ingredient (Araujo et al., 2015). 17% of the samples
studied contained caffeine, sometimes at concentrations> 20%, and
often samples sold under the same name at different stores showed an
utterly different composition (Araujo et al., 2015).
The most common synthetic cathinones in the United States are α-
pyrrolidinopentiophenone (α-PVP), 3,4-methylenedioxypyrovalerone
(MDPV), and pentedrone; while mephedrone and methylone are more
common in Europe (Barrios et al., 2016; Weinstein et al., 2017).
Cathinones act to inhibit monoamine transporters for the reuptake of
dopamine (DAT), serotonin (SERT) and norepinephrine (NET) blocking
the reuptake of these neurotransmitters; however, their activity is
complex due to varying selectivity for different transporters (Abbott
and Smith, 2015; Matsunaga et al., 2017). Adding to the complexity,
most cathinones also act as monoamine releasers, again with varying
selectivity for the three neurotransmitters (Abbott and Smith, 2015).
Synthetic cathinones have a rapid onset of action for psychostimulant
Table 2
Summary of case reports involving known or suspected intoxication with synthetic cannabinoids that had been vaped or were found in e-liquids for vaporization.
Ref Patient Clinical Signs Drug Identification
(Lam et al., 2017) 24 yrs. old male; confusion, agitation,
palpitation and vomiting following the oral
ingestion of 2 drops of e-cig fluid
GCS – 14/15; BP – 163/93mmHg; HR – 169 bpm;
12 lead ECG showed sinus tachycardia with
multiple ventricular ectopic beats
AB-FUBINACA (serum 5.6 ng/ml) and
ADB-FUBINACA (serum 15.6 ng/ml) identified in
e-cig fluid and serum
(McCloskey et al.,
2016)
36 yrs. old male; found “kicking” and “rolling”
around sidewalk; patient was holding an e-cig
BP – 151/56mmHg; HR – 106 bpm; Non-specific T
wave and ST segment changes; creatine kinase 3936
U/L
Patient admitted to placing K2 in e-cig to “get
high”
(Mehta et al., 2017) 16 yrs. old obese male; sudden onset of left-
sided chest pain following e-cig use
BP – 142/76mmHg; ECG showed non-specific ST
segment changes troponin I 1.63 ng/ml;
Urine screen positive for cannabinoids; suspected
intoxication with synthetic cannabinoids; no
verification
Fig. 2. Screen captures from forums discussing the use of illicit drugs in e-cigarettes or other forms of portable vaporizers. (a) Discussion on Quora.com about
whether you can smoke crystal meth from a vaporizer; (b) Discussion on Reddit.com about the use of electronic cigarettes to vape synthetic cathinones; (c) Discussion
on drugs-forum.com about cocaine e-liquid available for sale on the dark web; (d) Discussion on drugs-forum.com about vaporizing heroin in an e-cigarette.
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effects that can last for minutes to hours depending on the route of
administration (Abbott and Smith, 2015). They produce similar effects
to amphetamine with users reporting euphoria, increased sociability,
sexual arousal, empathy, and increased focus (Abbott and Smith, 2015;
Karila et al., 2015).
3.5.1. MDPV
3,4-methylenedioxypyrovalerone (MDPV) was one of the earliest
abused synthetic cathinones because of its strong psychostimulant ef-
fects (Anizan et al., 2014). in vitro data have shown that MDPV is a
potent inhibitor of catecholamine uptake at DAT and NET, with sig-
nificant preference for DAT and NET over SERT, but it does not cause
neurotransmitter release (Ellefsen et al., 2016; Kandel and Kandel,
2015; Matsunaga et al., 2017; Solis, 2017). Reported clinical features
include agitation, psychosis, paranoia, tachycardia, rhabdomyolysis,
hyperthermia, metabolic acidosis, acute renal failure and death (Anizan
et al., 2014; Froberg et al., 2015; Valsalan et al., 2017). In a case study
of 23 patients who tested positive to MDPV all except one were ad-
mitted to hospital and most were admitted to the ICU, with one re-
ported death (Froberg et al., 2015).
3.5.2. α-PVP
Between 2011–2015 there were at least 23 deaths where α-PVP was
the direct cause or contributed to the death (Kandel and Kandel, 2015).
Its mechanism of action closely resembles that of MDPV (Ellefsen et al.,
2016; Karila et al., 2015). It is more potent at both DAT and NET than
cocaine or amphetamine (Kandel and Kandel, 2015). Routes of ad-
ministration of α-PVP include snorting, injection, oral, smoking/in-
halation, sub-lingual and rectal (Kandel and Kandel, 2015). User re-
ports on forums have suggested that some believe that smoking, either
by vaporization or a pipe, leads to an increase in side effects (Kandel
and Kandel, 2015). Dosage reports vary from 20 to 330mg (Kandel and
Kandel, 2015). Features associated with α-PVP include tachycardia,
hyperthermia, hypertension, agitation, paranoia, hallucinations, ag-
gression, mydriasis, and insomnia (Kandel and Kandel, 2015; Patel
et al., 2017; Umebachi et al., 2016); however, toxic effects are often
difficult to ascribe due to polydrug use.
3.5.3. Mephedrone
Dosages of mephedrone vary considerably: oral doses range from 15
to 300mg; nasal insufflation doses range from 5 to 200mg; intravenous
or intramuscular injection doses are in the range 5–150mg; and the
rectal dose is ∼100mg (Papaseit et al., 2017). There are currently no
data in the literature describing vaporization doses. Redosing is
common due to a short duration of action, so this can lead to a total
dosage of 1–2 g administered in a single session (Busardo et al., 2015)
with psychoactive effects, which resemble those of methamphetamine,
lasting 1–4 hours (Karila et al., 2015). Mephedrone works on the
monoamine receptor systems with inhibition of the reuptake of neu-
rotransmitters at NET, DAT, and SERT, in combination with an increase
in the release of all three neurotransmitters (Karila et al., 2015; Luethi
et al., 2017). Adverse effects from mephedrone use include a change in
body temperature, agitation, mydriasis, slurred speech, blurred vision,
nausea, vomiting, and seizure (Busardo et al., 2015; Ellefsen et al.,
2016). Acute toxic effects include hypertension, tachycardia, chest
pain, paranoia, psychosis, and suicidal ideation (Papaseit et al., 2017).
There have been at least 12 documented cases where death was at-
tributed to mephedrone or multiple-drug intoxication involving me-
phedrone (Busardo et al., 2015).
3.5.4. Methylone
Methylone is a direct MDMA analog with the only structural change
being the incorporation of the β-keto group common to all synthetic
cathinones. As such its mechanism of action is similar to that of MDMA
and mephedrone (Barrios et al., 2016; Karila et al., 2015). There have
been at least four reported cases of death in the United States and one in
France related to toxicity from methylone use (Barrios et al., 2016).
3.5.5. E-cigarette usage
There is evidence of e-cigarette use of a variety of synthetic cath-
inones (including derivatives not detailed above) on illicit drug forums,
including the user’s perceived importance of the ability to consume
drugs via stealth in public (Fig. 2). Additionally, there is literature
evidence that MDPV has been administered by vaporization (Schifano
et al., 2017) and that e-cigarettes are being used to vaporize drugs such
as methamphetamine and α-PVP as vaporization has a more rapid onset
of effects and a shorter duration of action when compared to nasal
inhalation (snorting; Marusich et al., 2016). Blundell et al. (2018a)
provided additional evidence of the use of electronic vaping devices to
vape synthetic cathinones with a convenience survey suggesting that
8.5% of electronic vaping device users had vaped mephedrone and
7.1% had vaped α-PVP.
3.6. Cocaine
Cocaine is the second most common illicit drug globally and is a
central and peripheral nervous system stimulant (Favrod-Coune and
Broers, 2010). Cocaine is known colloquially as ‘coke’ in its hydro-
chloride salt form and ‘crack’ in its free base form. Some users distin-
guish crack from freebase cocaine upon the basis that crack is a more
impure form of the drug. Intranasal, intravenous, and inhalational are
the most common routes of administration (Benowitz, 2012b). The
main mechanism of action of cocaine is blocking the reuptake of
monoamine neurotransmitters, norepinephrine, dopamine (Docherty,
2008; Heikkila et al., 1975) and to a lesser extent serotonin (Howell and
Kimmel, 2008; Rothman et al., 2001). This results in central and per-
ipheral nervous system stimulation (Favrod-Coune and Broers, 2010).
Further to this, cocaine stimulates alpha adrenergic receptors and
blocks voltage-gated membrane sodium channels, with a notable effect
on myocardial electrical conduction (Magnano et al., 2006; Tisdale
et al., 1996).
3.6.1. Dosage required for toxicity
Although inhaled ‘crack’ cocaine reaches the brain quickly, its short-
term effects tend to increase redosing, which leads to a high risk of
toxicity and a rapid development of dependence (Garcia et al., 2012).
Dosages are also difficult to determine as the user can space the in-
halation of the single ‘rock’ of crack cocaine over several hours. The
dosage causing toxicity varies greatly by route of administration and
individual tolerance level (Benowitz, 2012b). Ingestion of one gram or
more is suggested to be fatal (Benowitz, 2012b) although large ranges
have been reported (EMCDDA, 2015a; Heard et al., 2008).
3.6.2. Toxic effects
Possible toxic effects include myocardial infarction, cerebrovascular
accident, ventricular tachycardia and ventricular fibrillation, seizures,
paranoia, hyperthermia, bizarre and violent behavior (Baselt, 2011),
QRS prolongation, Q–T prolongation, respiratory arrest, delirium,
psychosis, anxiety, muscle rigidity (Benowitz, 2012b), blurred vision
and nausea (Brownlow and Pappachan, 2002). Inhalation of ‘crack’
cocaine has also been associated with more violent behavior and ag-
gression when compared with the use of the hydrochloride salt of co-
caine (Garcia et al., 2012).
3.6.3. E-cigarette usage
Illicit drug forums suggest that cocaine in its free base form (crack
cocaine) is being used in electronic cigarette style devices with users
stating that e-liquids containing cocaine are available for purchase on
the dark web (Fig. 2). Survey data found that 10.9% of electronic
vaping device users had vaped cocaine powder and 8.4% had vaped
crack cocaine (Blundell et al., 2018a). The majority of the respondents
to this survey used e-cigarettes as their preferred vaping device
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(74.2%). The melting point for the hydrochloride salt of cocaine is
195 °C however at the vaporization temperature the cocaine decom-
poses (Hatsukami and Fischman, 1996). Cocaine can be converted from
the hydrochloride salt to the freebase form which can be volatilized at
∼100 °C, however at temperatures exceeding 200 °C the loss of the
benzoyl group via an elimination reaction begins to occur (Bell and
Nida, 2015). Thermolytic degradants, which may be generated in the
process of heating to vaporization, for cocaine and methamphetamine
include both potential carcinogens and psychoactive pyrolysis products
(Marusich et al., 2016).
3.7. Heroin
Heroin is an opioid, working as a central nervous system depressant,
which is most commonly injected intravenously but can also be inhaled
or snorted intranasally. (EMCDDA, 2015b; Rook et al., 2006). Following
administration of heroin, it crosses the blood-brain barrier and is ra-
pidly converted into 6-monoacetylmorphine (6-MAM) and then into
morphine (Rook et al., 2006; Selley et al., 2001), along with other
metabolites such as the toxic morphine-3-glucuronide (M3G) (Rook
et al., 2006; Smith, 2000). Heroin, 6-MAM, and morphine show a strong
affinity for the μ-opioid receptor and exhibit the effects of heroin via its
activation (Selley et al., 2001).
3.7.1. Dosage required for toxicity
The inhalation method known as ‘chasing the dragon,’ where users
inhale heroin vapor from a heated metal surface, has been a common
method of administration of heroin for almost a century. However, data
on usual dosages and toxic dosages is limited due to the variation in
dosage in opioid naïve and tolerate users as well as the nature of the
technique which involves many incremental small doses until the de-
sired physical effects are reached. For IV administration, the minimum
lethal dosage is claimed to be 200mg noting larger dosages for chronic
uses with built up tolerance (EMCDDA, 2015b). Fatalities have been
recorded following 10mg IV dosages (Clarke and Moffat, 1986).
3.7.2. Toxic effects
Agitation, hallucinations, paranoia, sinus tachycardia, seizures
(Dart, 2004), lethargy, hypotonia, apnea, leukoencephalopathy, pul-
monary edema, coma, and sudden death have been reported following
heroin use (Albertson, 2012). Pyrolysis products from vaporizing heroin
at high temperatures have been shown to induce encephalopathy (Bell
and Nida, 2015), inhalation of heroin has also been shown to cause
acute eosinophilic pneumonia (Eyupoglu et al., 2017).
3.7.3. E-cigarette usage
Illicit drug forums suggest that the freebase form of heroin is being
used in personal electronic devices such as e-cigarettes (Fig. 2). A
convenience survey found that 7.1% of responding electronic vaping
device users had vaped heroin (Blundell et al., 2018a). There is also
evidence on illicit drug forums of other opioids including oxycodone
and morphine being used in e-cigarettes.
3.8. Fentanyl and derivatives
Fentanyl is an agonist at all opioid receptors with 50–100 times the
potency of morphine. The potency of fentanyl analogs varies with
carfentanil being 10,000 times more potent than morphine. The high
lipophilicity of these compounds results in rapid diffusion through
membranes, including the blood-brain barrier, with a subsequent rapid
fall in plasma concentration. The lipophilicity also complicates the
pharmacokinetics in patients with large amounts of adipose tissue due
to storage and slow release of the opioid. Effects of fentanyl and its
derivatives are similar to that of other opioids including analgesia,
anxiolysis, euphoria, and drowsiness (Suzuki and El-Haddad, 2017).
Fentanyl and its derivatives are of particular importance at the moment
given their role in the current opioid epidemic, with 19,413 deaths in
the United States in 2016 attributed to synthetic opioids, more than
double the number in 2015 (Hedegaard et al., 2017).
3.8.1. Dosage required for toxicity
The clinical effects of fentanyl are dosage dependent with dosages
varying greatly between analogs. For fentanyl, serum concentrations of
0.3–0.7 ng/ml provide analgesia and concentrations> 3 ng/ml cause a
loss of protective airway reflexes and CNS depression in opioid naïve
patients (Kumar et al., 1987; Nelson and Schwaner, 2009) however,
toxic dosages are far more difficult to predict in those with an opioid
tolerance. Postmortem serum concentrations have been in the range of
3–383 ng/ml (Martin et al., 2006).
3.8.2. Toxic effects
Constipation, nausea, pruritus, orthostatic hypotension, chest wall
rigidity (Armenian et al., 2017), confusion, hallucinations, weakness,
and seizures are all possible toxic effects (DrugAbuse.com, 2018). In
cases of overdose, signs include extreme fatigue, obtundation, cardiac
arrest, bradypnoea, severe confusion, and respiratory arrest
(DrugAbuse.com, 2018).
3.8.3. E-cigarette usage
A survey study by Blundell et al. (2018a) found that 7.3% of elec-
tronic vaping device users had vaped fentanyl (2.5% of all survey re-
spondents). In the literature, there is a case report of a 36-year old male
presenting to the emergency department with altered mental status
following vaping combined with oral consumption of ‘synthetic opium’
which upon further analysis was discovered to contain acetylfentanyl
(Rogers et al., 2016). There is also a case report of a fatal intoxication
with fentanyl derivative, 4-fluorobutyrfentanyl (4-FBF). A 26-year old
male was found deceased with an e-cigarette near the body. 4-FBF was
identified in both biological samples (blood concentration of 4-FBF was
91 ng/ml) and the e-cigarette fluid (Rojkiewicz et al., 2017).
3.9. Other drugs
3.9.1. E-cigarette usage
A sample of resin submitted for testing by a concerned parent was
found to be a concentrated resin from the blue lotus flower (N. caerulea)
for suspected use in an e-cigarette ‘dripper-style’ device (Poklis et al.,
2017). The confiscated resin was shown to contain a very high con-
centration of Nuciferine (4300 ng/ml), an alkaloid associated with do-
pamine receptor blockade. Subsequent investigation led to the identi-
fication of a number of blue lotus flower e-liquids and resins on sale for
use in e-cigarettes (Poklis et al., 2017).
In addition to a number of illicit drugs already discussed re-
spondents to Blundell et al. (2018a) recent survey of e-cigarette users
also self-reported use of tryptamines (7.0%), NBOMe (2,5-dimethoxy-4-
bromophenethylamine) (6.9%) and ketamine (6.7%).
Of all the drugs analyzed in this study only gamma-hydroxybutyric
acid (GHB) and 3,4-methylenedioxyamphetamine (MDA) were found to
have no evidence of use in e-cigarettes in either the literature or on
illicit drug forums. This may be due to the well-established oral dosing
behaviors of GHB, and the less frequent present-day abuse of MDA.
4. Discussion
In highlighting the risk of e-cigarettes being used as illicit drug
delivery systems, the focus must be directed on the groups who are at
the greatest potential risk, as well as whether this route of drug ad-
ministration holds a benefit of risk reduction in users. The demo-
graphics of e-cigarette users as well as those experimenting with the
technology show an alarming trend towards adolescents and young
adult use and experimentation (Anand et al., 2015; Goniewicz and
Zielinska-Danch, 2012), a pattern which is mirrored in illicit drug
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exposure (AIHW, 2008). The use or experimentation with e-cigarettes
has also demonstrated the risk of commencing or experimenting with
traditional cigarettes (Dutra and Glantz, 2014; Leventhal et al., 2015).
Considering that e-cigarettes are being marketed and reported as a safe
alternative to smoking (Rom et al., 2015), a statement supported by
current youth perceptions (Ambrose et al., 2014; Anand et al., 2015),
potential illicit drug administration via this route may present itself as a
safer and innocuous method to experiment and try illicit drugs. This
view of harm minimization, cleaner administration, potential entice-
ment from liquid flavorings (Durmowicz, 2014) and reduced risk may
result in experimentation and use within this at-risk group which may
not have otherwise occurred. Adding to this, the benign appearance of
e-cigarette fluid may also mask the appearance of illicit drugs resulting
in unintended or malicious exposure. With the growth of the e-cigarette
industry and user adoption, there has been an observed spike in
emergency department visits, and poison hotline calls associated with
pediatric accidental exposure to the e-cigarette fluid or inhalational
vapor (Cantrell, 2014; Vakkalanka et al., 2014). This raises the possible
reality of pediatric exposure to either dissolved illicit drugs in e-cigar-
ette fluid or accidental inhalation of illicit drug vapor.
The implications of illicit drug use via e-cigarettes poses issues for
medical practice, public health, and policing forces. The use of illicit
drugs via an easy to administer route and tool may result in higher
usage levels and maintenance of drug trough levels resulting in higher
thresholds for drug toxicity as well as changes in drug withdrawal. It
may also lead to unusual patterns of drug use (continuous versus acute
administration), potential increases in young adult use, addiction and
toxicity, and pediatric accidental exposure. This has important im-
plications for frontline healthcare workers such as general practitioners,
emergency physicians and drug and alcohol workers. Many of these
facets have carried on implications for public health as well. The de-
batable efficacy in e-cigarettes as a nicotine cessation device (Orr and
Asal, 2014) raises questions of their benefit to society as a harm
minimization tool. In relation to police enforcement of illegal drugs, e-
cigarettes pose a massive challenge for detection and public place
usage. Dissolving illicit drugs into e-cigarette fluid poses problems of
visual identification of illicit drugs by police forces. Further to this,
some users on illicit drug forums have reported that characteristic
smells produced by the combustion of illicit drugs are lost during
vaping, potentially allowing users to ingest illicit drugs in public loca-
tions without alerting authorities and possibly exposing the general
public to second-hand vapor. This is of particular concern in locations
where e-cigarettes are not policed under the same restrictions as tra-
ditional combustible cigarettes.
Though the current study aimed to highlight the potential risk of e-
cigarettes as a novel illicit drug delivery system, as well as highlight
potential current usage trends, the authors, acknowledge that the
sources used to obtain such trends are not ideal. Future research should
continue surveying e-cigarette usage and whether users have con-
sidered or used illicit drugs with the technology. Current studies are
limited with small sample sizes, such as a study of club patrons in South
London which found that 5.9% of individuals (N= 101) had used an e-
cigarette to vape substances other than nicotine (Thurtle et al., 2017). A
survey study using US college students determined that 6.94% of e-
cigarette users have used their e-cigarette to vape something other than
nicotine. In the majority of these cases the students identified cannabis
(77.9%) as the substance used; however, 16.4% refused to indicate or
did not know the identity of the drug vaped (Kenne et al., 2017). Data
currently being collected by the Global Health Survey may go some way
to rectifying this gap in current understanding (Winstock, 2017). All
researchers investigating the use of e-cigarettes or other portable
electronic devices as a means of vaping illicit drugs need to ensure that
the terms they are using are clearly explained to differentiate between
the different types of vaporizing devices. Additionally, survey designers
need to be made aware of the changing nature of ‘smoking’ versus
‘vaping’ terminology to ensure the validity of their results.
Perhaps most telling in the examination of the extent of e-cigarettes
and other electronic vaping devices to inhale illicit drugs are the recent
survey results published by Blundell et al. (2018a). Of the 861 (34.4%)
respondents that had used an electronic vaping device, more than one
third (39.5%) had used them to vape recreational drugs. The most
common drug vaped in this study was cannabis (18.0% of vape device
users). However, there was evidence of a wide range of drugs being
vaped by electronic vaping device users including: MDMA (11.7%);
cocaine powder (10.9%); crack cocaine (8.4%); synthetic cathinones,
mephedrone (8.5%) and α-PVP (7.1%); synthetic cannabinoids (7.8%);
opioids, heroin (7.1%) and fentanyl (7.3%); and other drugs including
tryptamines and ketamine (Blundell et al., 2018a). This paper provides
the first evidence in the scientific literature as to the broad range of
drugs currently being used in e-cigarette-style devices.
The e-cigarette industry and user base is a rapidly expanding area,
along with the foundation of literature reviewing it. This study has
highlighted a gap in the literature pertaining to e-cigarettes as a de-
livery system for illicit drugs. Where the literature fails to account for
these emerging behaviors, illicit drug forums provide some insight. This
provides the academic community the opportunity to start doc-
umenting the use of e-cigarettes with illicit street drugs and start pro-
viding advice to health professionals, public health, and policing forces.
The adoption by the illicit drug using community demonstrates the
viability and risk of e-cigarettes being used as an illicit drug delivery
system, and also poses the question of its use as a delivery system for
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